Proteasome inhibition represents a valid anti-tumor approach and its use has been validated in Waldenstrom's macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-target effects. Selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive-(c20S) and immuno-(i20S) proteasome represents a sufficient and successful strategy to induce anti-neoplastic effect in hematologic tumors. We therefore studied ONX0912, a novel selective, irreversible inhibitor of the CT-L activity of i20S and c20S. We showed that primary WM cells express higher level of i20S compared to c20S; and that ONX0912 inhibited the CT-L activity of both i20S and c20S, leading to induction of toxicity in primary WM cells; as well as of apoptosis through c-jun-N-terminal-kinase activation; NF-kB inhibition; caspase cleavage; and initiation of the unfolded protein response. Importantly, ONX0912 exerted toxicity in WM cells, by reducing bone marrow (BM)-derived IL-6 and IGF-1 secretion, thus inhibiting BM-induced p-Akt-and p-ERK-activation in WM cells. These findings suggest that targeting i20S and c20S CT-L activity by ONX0912 represents a valid anti-tumor therapy in WM.
Introduction
The multicatalytic ubiquitin-proteasome pathway plays an important role in the targeted degradation of a wide spectrum of proteins involved in the regulation of several cellular processes responsible for the maintenance of cellular homeostasis. 1 encoded by the β5, β2, and β1 subunits, respectively. 2 Similarly, cells of hematopoietic origin express the immunoproteasome, which retains the structural subunits of the constitutive proteasome but exerts its enzymatic activities through the catalytic subunits LMP7, MECL1 and LMP2 which form the 20Si core. [3] [4] [5] Specific targets for proteasome degradation include several proteins involved in cell-cycle regulation, cell proliferation, programmed cell death, and stress response. These findings validate targeting the proteasome for cancer therapy. Indeed, a wide spectrum of compounds, both natural and synthetic, has been identified as proteasome inhibitors, with bortezomib being the first proteasome inhibitor to enter clinical trials and receive approval for the treatment of patients with multiple myeloma (MM). 6, 7 A recent report has shown that B-cell malignancies are characterized by a preferential expression of the i20S; and that a selective inhibition of the CT-L activity of the proteasome, both at the constitutive and immunoproteasome level, is sufficient to exert an anti-neoplastic effect in hematologic malignancies. 8 In the present study, we
show that primary WM cells are characterized by higher expression of the i20S immunoproteasome subunits as compared to c20S subunits and that they contain a higher i20S content as compared to normal CD19+ B-cells. We therefore investigated for the first time the anti-tumor activity of the novel orally bioavailable and selective peptide epoxyketone proteasome inhibitor ONX0912 in WM. Our findings demonstrate that
ONX0912 inhibits the chymotrypsin-like activity of both the immunoproteasome (LMP7)
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From and the constitutive proteasome (β5) in WM cells, leading to induction of cytotoxicity in primary WM cells; as well as of programmed cell death in a caspase-dependent andindependent manner, as shown by activation of c-jun-N-terminal kinase; inhibition of NF-kB; and initiation of the unfolded protein response. Importantly, ONX0912 exerted cytotoxicity in WM cells, even in the context of bone marrow milieu. We also showed that combination of ONX0912 and bortezomib acted synergistically in inhibiting the i20S and c20S CT-L activities; NF-kB activity; and caspase-and PARP-cleavage; thus inducing synergistic cytotoxicity in WM cells. Taken together, these findings provide the pre-clinical rational for testing ONX0912 in Waldenstrom Macroglobulinemia.
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Material and methods

Cells
Primary WM cells were obtained from bone marrow (BM) samples from previously treated WM patients using CD19
+ microbead selection (Miltenyi Biotec, Auburn, CA) with over 90% purity, as confirmed by flow cytometric analysis with monoclonal antibody reactive to human CD20-PE (BD-Bioscience, San Jose, CA). The WM and IgM secreting low grade lymphoma cell lines (BCWM.1; MEC.1; RL) were used in this study. 9 Peripheral blood mononuclear cells (PBMCs) were obtained from healthy subjects by Ficoll-Hipaque density sedimentation and CD19+ selection was performed as described above. All cells were cultured at 37°C in RPMI-1640 containing 10% fetal bovine serum (FBS; Sigma Chemical, St Louis, MO), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (GIBCO, Grand Island, NY 
Flow cytometric analysis
Cell-cycle analysis was profiled by flow cytometry using propidium iodide (PI) staining (5 μ g/mL, Sigma Chemical) after 24 hour culture with PR-047, as described.
9
DNA fragmentation assay
Cell Death Detection ELISA (Roche Applied Science, Indianapolis, IN) was used to quantitate DNA fragmentation, as per the manufacturer's instructions.
Immunoblotting
WM and IgM secreting cell lines were harvested and lysed using lysis buffer (Cell Signaling Technology, Beverly, MA) reconstituted with 5 mM NaF, 2 mM Na 3 VO 4 , 1 mM PMSF (polymethilsulfonyl fluoride), 5 μg/mL leupeptine, and 5 μg/mL aprotinin.
Whole-cell lysates (50 μg/lane) were subjected to sodium dodecyl sulfate-polyacrylamide gel eletrophoresis (SDS-PAGE) and transferred to polyvinyldene fluoride (PVDF) membrane (Bio-Rad Laboratories, Hercules, CA). The antibodies used for
(Thr202/Tyr204), -ERK1/2, , -caspase-3, -caspase-8, -caspase-9, -PARP, , βcatenin, GRP94, PERK, p-EIF2α, BIP, PDI, ATF, p-MKK7, p-SAPK/JNK, -p27 kip1 , -p21 Cip1 , cyclinD1, -cylcinD2, cyclinE, -nucleolin, -p-p65, -p65, -p105, -p50, -p100, -p52, -RelB, 
Proteasome Constitutive Immuno Subunit ELISA assay (ProCISE)
The ProCISE assay was performed as previously described. 8 Briefly, human 
20S proteasome activity
The chymotrypsin-like activity of the 20S proteasome of primary WM tumor cells was determined by measurement of fluorescence generated from the cleavage of the fluorogenic substrate suc-LLVY-amc, as described. 2C ). In contrast, ONX0912 did not exert cytotoxicity on normal PBMC-derived CD19+ isolated from 4 healthy volunteers (Fig. 2D) . We have previously showed that ONX0912-dependent inhibition of CT-L activity occurs after 2 hours, while induction of cytotoxicity has been observed at 24 hours, with an increasing effect at 48 and 72 hours.
Given the irreversible nature of the proteasome inhibition exerted by ONX0912 in WM and IgM secreting low grade lymphoma cell lines, this could potentially indicates that cell death is either a delayed effect of inhibited CT-L activity, or that it depends on other deferred mechanisms. We therefore performed a wash out experiment, where cells where treated with ONX0912 for 2 hours; subsequently washed and replaced with fresh medium in absence or ONX0912. We found that there is induction of cytotoxicity, indicating that ONX0912-dependet cytotoxicity may results from both CT-L proteasome inhibition and delayed effects due to other ONX0912 induced mechanisms (Fig. 2E ).
We next demonstrated that ONX0912 induced apoptosis in a dose-dependent manner, as assessed by DNA fragmentation (Fig. 2F ). Similar effects were obtained on other IgM secreting low grade lymphoma cell lines (RL, MEC.1: Fig. 2F ). We also examined the molecular mechanisms whereby ONX0912 induces cytotoxicity in WM, and demonstrated that ONX0912 induced caspase-8, -9, -3 and PARP cleavage in a dose dependent manner (Fig. 2G ). It is known that proteasome inhibition eradicates tumor cells, partly by initiating the unfolded protein response (UPR), a signaling cascade activated by the accumulation of misfolded proteins in the endoplasmic reticulum (ER). 11 Previous reports indicate that induction of ER stress in WM cells may represent a valid therapeutic option in WM. 12 We therefore sought to investigate the effect of ONX0912 in modulating the expression of unfolded protein response (UPR) components in WM cells as one of the mechanisms of cytotoxicity in WM cells. We found that ONX0912 induced accumulation of β-catenin, consistent with a previous report. 13 In addition, ONX0912
induced up-regulation of UPR components such as GRP94; PERK followed by PERKdependent phosphorylation of EIF-2α. Consistent with terminal UPR induction by ONX0912, ATF4 protein level was increased in WM ONX0912-treated cells.
We observed a ONX0912-dependent down-modulation of PDI and BiP, at 12 hours (Fig. 2G) ; and hypothesized that early exposure time (12h) induces downmodualtion of BiP and PDI leading to reduced cell survival and induction of apoptosis in the treated cells; however, longer exposure (48h) could result in up-regulation of BiP and PDI due to induction of UPR. We therefore treated cells with ONX0912 (10-50nM) for 12 and 48 hours, and cell lysates were subjected to Western blot. We found downmodulation and up-regulation and of PDI and BiP, at 12h and 48h, respectively. In parallel, p-EIF2α protein expression increases upon ONX0912, at either 12h or 48h ( indicating that ONX0912 triggers apoptosis also through other mechanisms different than caspase activation or ER stress modulation.
We therefore sought to determine other mechanisms as regulators of ONX0912-induced cytotoxicity. We showed that ONX0912 treatment also triggered MKK-7- and p27 kip1 (Fig. 4D) .
ONX0912 inhibits the canonical and non canonical NF-kB pathways
NF-kB pathway plays a pivotal role in regulating growth and survival of plasma cell malignancies and, inhibition of NF-kB represents one of the mechanisms of action for proteasome inhibitors. 14 We therefore sought to investigate whether ONX0912 could target this pathway.
We first investigated the effect of ONX0912 on the p65NF-kB DNA binding activity, studying nuclear extracts from treated cells using the Active Motif assay. We
showed that TNF-α treatment induced NF-κB recruitment to the nucleus in BCWM.1 cells, which was inhibited by ONX0912 in a dose-dependent manner (Fig. 5A) .
Moreover, immunoblotting from nuclear extracts demonstrated that p65 phosphorylation and p50/p105NF-kB expression were inhibited by ONX0912 (Fig. 5B) . We next examined whether ONX0912 could target the non-canonical NF-kB pathway.
Immunoblotting of nuclear extracts showed that ONX0912 inhibited the expression of p100/p52 and RelB, which are mostly activated through the non-canonical pathway (Fig.   5B) . 15 We next investigated the role of ONX0912 on the expression of NF-kB negative regulator IkB in the cytoplasmic compartment, and found that ONX0912 up-regulated its expression (Fig. 5C ). Taken together, these data demonstrate that ONX0912 regulates both canonical and non-canonical pathways of NF-κB in WM cells.
Effect of ONX0912 and bortezomib in inducing WM cells cytotoxicity
ONX0912 exerts a different inhibitory profile on proteasome activities compared to bortezomib. 16 Previous reports indicate that bortezomib mainly targets the CT-L activity and to a lesser degree the C-L activity; 17 while ONX0912 mainly affects the CT-L; 16 but the effect of ONX0912 and bortezomib in inhibiting the immunoproteasome and the constitutive proteasome activities has not been evaluated. Moreover, previous reports demonstrate synergism between different classes of proteasome inhibitors. 17 We therefore sought to determine the effect of ONX0912 and bortezomib, either used as single agents or in combination, in targeting the CT-L activity of both constitutive proteasome and immunoproteasome. WM cells were treated with ONX0912 (10-20nM), bortezomib (2.5-5nM), alone or combination, for 2 hours. ONX0912 showed a significant increase in inhibiting CT-L activity of both the i20S (LMP7; Fig. 6A ) and the c20S (β5; Fig. 6B) when combined with bortezomib in WM cells. Specifically, ONX0912 (10nM) induced inhibition of the LMP7 activity in 40% of the treated cells, which was increased to 62%
and 73% in the presence of bortezomib at 2.5nM (combination index, C.I.: 0.870) and 5nM (C.I.: 0.812), respectively, indicating additive effect (Fig. 6A) . Similar effect was also observed using ONX0912 and bortezomib in targeting the β5 activity (Fig. 6B ).
We next investigated whether the ONX0912/bortezomib-dependent effect on targeting the CT-L activity could lead to either additive or synergistic induction of Figure 6D . To better define the mechanisms of combined ONX0912 plus bortezomib-induced WM cytotoxicity, we investigated the effect of ONX0912 (20-50nM), either alone or in combination with bortezomib 10nM, using immunoblotting after 12 hours treatment. Interestingly, we demonstrated that PARP-, caspase-9-, -3-, and -8-cleavage were significantly higher using the combination compared to each agent alone (Fig. 6E) .
We finally, sought to investigate whether the combination of the two proteasome inhibitors would lead to synergistic modulation of NF-kB pathway. We first investigated the effect of ONX0912, either alone or in combination with bortezomib, on the NFκBp65 DNA binding activity, studying nuclear extracts from treated cells using the Active Motif assay. We showed that TNF-α treatment induced NF-κB recruitment to the nucleus in BCWM.1 cells, which was inhibited to a greater extent by ONX0912 than bortezomib, and more significantly by the combination of the two proteasome inhibitors (Fig. 6F) . Moreover, immunoblotting from nuclear extracts demonstrated that p65 phosphorylation was inhibited by ONX0912, either alone or in combination with bortezomib, more than by bortezomib as single agent (Fig. 6G) . Next, proteins isolated from the cytoplasmic compartment were examined, and we found that the NF-kB inhibitory protein IkB was more significantly increased upon ONX0912 plus bortezomib than single agent exposure (Fig. 6G ). which was inhibited by ONX0912 in a dose-dependent manner (Fig. 7A) .
The PI3K/Akt pathway is implicated in promoting growth and survival of tumor B cells, including WM. 19, 20 We therefore examined the effect of ONX0912 on Akt release. 22 We therefore tested the activity of ONX0912 in modulating p-Akt and p-ERK signaling pathways in WM cells in the context of BM milieu, by determining the effect of ONX0912 in IL-6 and IGF-1 secretion from primary BMSCs and found that ONX0912 reduced secretion of both IL-6 and IGF-1 from the BM milieu in a dose-dependent manner ( Fig. 7B; Fig. 7C ). Since IL-6 and IGF-1 are known to induce Akt and ERK phosphoryaltion, 23 We next measured the efficacy of ONX0912 in inhibiting IL-6 and IGF-1 secretion from primary WM BMSCs, using neutralizing IL-6 and IGF-1 antibodies as controls. We demonstrated that ONX0912-induced inhibition of IL-6 and IGF-1 in BMSCs conditioned medium was comparable to the effect obtained using anti-IL-6-and
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From anti-IGF-1-neutralizing antibodies ( Fig. 7E; Fig. 7F ). We next sought to test the efficacy of ONX0912 in overcoming BMSC-induced growth, compared to the effect obtained upon anti-IL-6 and anti-IGF-1 neutralizing antibodies; and found that ONX0912 inhibited BMSC-induced WM cell growth as effectively as using anti-IL-6-and anti-IGF-1-neutralizing antibodies (Fig. 7G) , suggesting that ONX0912 may trigger significant antitumor activity against WM cells in the presence of the BM milieu due to its inhibitory effect on IL-6 and IGF-1 secretion from the BM microenvironment. Moreover, addition of exogenous IL6 and IGF1 partially blocked ONX0912-depenent cell growth inhibition (Fig. 7G) . Absence of anti-IL-6-and anti-IGF-1-induced cytotoxicity on BMSCs was observed (data not shown). One of the most extensively studied proteasome inhibitors is bortezomib (Millennium Inc, Cambridge, MA). Bortezomib reversibly inhibits the ubiquitin-26S
proteasome pathway, which regulates the turnover of a vast number of intracellular proteins, and has become an exciting target in a variety of malignancies, most notably multiple myeloma. 27 The proper functioning of this system is crucial for cell cycle regulation, gene transcription, and signal transduction. Based on its activity in multiple myeloma, single agent bortezomib was tested in WM in phase II trials and achieved 40-80% responses. 28 Nevertheless, a significant number of patients develop resistance to therapy or have neurological toxicity due to its inhibition of non-proteasome targets; 28 therefore, preclinical evaluation of new proteasome inhibitors is needed in order to improve patient outcome. Subsequently, a new irreversible, parenterally administered, peptide epoxyketone proteasome inhibitor, carfilzomib, has been developed. Its anti-tumor activity has been demonstrated in vitro in MM, 29 and it has shown promising activity in a Phase II clinical trial in patients with relapsed refractory MM. 30 Recently, ONX0912, a new orally bioavailable analogue of carfilzomib with a selective inhibitory effect of the CT-L activity of both immunoproteasome and constitutive proteasome has been developed in order to improve dosing flexibility and patient convenience over intravenously administered agents. 16 Importantly, it has been recently demonstrated that a selective and specific dual inhibition of the CT-L activity of the i20S (LMP7) and c20S
(β5) represents a sufficient and successful strategy to induce anti-neoplastic effect in hematologic tumors, as shown by using carfilzomib in T-cell leukemia, Burkitt's lymphoma and multiple myeloma, without causing cytotoxicity in non-transformed cells. 8 In contrast, inhibition of all the proteasome enzymatic activities induces cytotoxicity in non-transformed cells, which may be responsible for a significant induction of peripheral neuropathy as well as of any other toxicity. Therefore new proteasome inhibitors with a selected CT-L inhibitory activity, such as ONX0912 have been developed. 16 Preclinical pharmacology and in vitro characterization of ONX0912
have demonstrated a favorable toxicologic profile and an irreversible dose-dependent inhibition of the CT-L activity of the 20S and 20Si, with >80% proteasome inhibition in most tissues upon ONX0912 doses 4-10 fold below the maximum tolerated dose. 16 In the present studies, we first characterized the distribution of the i20S and c20S subunits in WM primary cells and in their normal cellular counterpart; primary cells express a significantly higher level of i20S subunits compared to c20S, and expression level of i20S and c20S components is significantly higher than in normal cells. We next (A) BCWM.1 cells were cultured with ONX0912 (0-100nM) for 4 hours, and then TNF-α (10ng/mL) was added for the last 20 minutes. NF-kBp65 transcription factor-binding to its consensus sequence on the plate-bound oligonucleotide was studied from nuclear extracts. Wild type and mutant are wild type and mutated consensus competitor (B) BCWM.1 cells were cultured with ONX0912 (0-100nM) for 4 hours, and TNF-α (10ng/mL) was added for the last 20 minutes. Nuclear extracts were subjected to western blotting using anti-p-NF-κBp65, -p65, -p105, -p50, -p100, -p52, -RelB and -nucleolin antibodies. (C) BCWM.1 cells were cultured with ONX0912 (0-100nM) for 4 hours, and TNF-α (100ng/mL) was added for the last 20 minutes. Cytoplasmic extracts were subjected to western blotting using anti -p-IκB, and -actin antibodies. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
